glp-1 agonist moa Frontiers Frontiers | Mechanisms of action

Doctor-developed bundle cultivating targeted restoration across the Gut-Metabolic Axis: GLP-1 boosting + Weight Support + Digestive Support + Heart and Circulatory Support + Caffeine-Free Energy

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease

It acts as a bispecific molecule, combining GLP-1 receptor agonism with GIP receptor antagonism to promote weight loss

However, the drugs alterations in gut motility may account for many of their commonly reported adverse effects including nausea, vomiting, early satiety, dyspepsia, and bowel habit changes

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

WHO Guidelines